enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Guanfacine - Wikipedia

   en.wikipedia.org/wiki/Guanfacine

   In 2010, guanfacine was approved by the FDA for the treatment of attention deficit hyperactivity disorder for people 6 to 17 years old. [16] It was approved for ADHD by the European Medicines Agency under the name Intuniv in 2015. [61] It was added to the Australian Pharmaceutical Benefits Scheme for the treatment of ADHD in 2018. [62]

3. Management of attention deficit hyperactivity disorder

   en.wikipedia.org/wiki/Management_of_attention...

   Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD.Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents, psychological or behavioral approaches, combined pharmacological and behavioral approaches, cognitive training ...

4. List of investigational attention deficit hyperactivity ...

   en.wikipedia.org/wiki/List_of_investigational...

   This is a list of investigational attention deficit hyperactivity disorder drugs, or drugs that are currently under development for clinical use in the treatment of attention deficit hyperactivity disorder (ADHD) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in ...

5. What’s the best treatment for ADHD? Large new study ... - AOL

   www.aol.com/news/best-treatment-adhd-large-study...

   A new study has investigated how different medications and therapies compare with placebos in treating ADHD symptoms. (Kobus Louw/E+/Getty Images) Get inspired by a weekly roundup on living well ...

6. Serdexmethylphenidate - Wikipedia

   en.wikipedia.org/wiki/Serdexmethylphenidate

   Serdexmethylphenidate is a prodrug of dexmethylphenidate created by the pharmaceutical company KemPharm (now Zevra Therapeutics). The compound was first approved by the FDA as one of the active ingredients in Azstarys for the treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults in March 2021.

7. Viloxazine - Wikipedia

   en.wikipedia.org/wiki/Viloxazine

   Viloxazine is indicated to treat attention deficit hyperactivity disorder (ADHD) in children age 6 to 12 years, adolescents age 13 to 17 years, and adults. [1]Analyses of clinical trial data suggest that viloxazine produces moderate reductions in symptoms; it is about as effective as atomoxetine and methylphenidate but with fewer side effects.